Accepted
at 9:32 a.m. May, 17, 2024
by
beejumm
Author:
beejumm
Type of change:
Other
Rationale for change
current structure makes it unclear what is the antagonist
Extra was not edited when aromatase inhibitors was added (see history)
Before
After
Extra
Extra
Extra
Extra
Text
Women who are at increased risk for breast cancer and low risk for adverse medication effects should receive:
{{c1::Tamoxifen, raloxifene, or aromatase inhibitors::3 options}}
{{c1::Tamoxifen, raloxifene, or aromatase inhibitors::3 options}}
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - Pharmacology: Selective Estrogen Receptor Modulators
Watch associated Bootcamp video - Cellular Injury and Neoplasia: Cell Cycle Independent Drug Targets
Watch associated Bootcamp video - Principles of Oncology and Therapeutics: Cell Cycle Independent Drug Targets
Watch associated Bootcamp video - Cellular Injury and Neoplasia: Cell Cycle Independent Drug Targets
Watch associated Bootcamp video - Principles of Oncology and Therapeutics: Cell Cycle Independent Drug Targets
OME
Additional Resources
One by one
Empty field


